Patients must not have clinical evidence of central nervous system involvement by lymphoma; if performed, any laboratory or radiographic tests performed to assess central nervous system (CNS) involvement must be negative
Known central nervous system involvement by PTCL
Patients with evidence of current central nervous system leukemic involvement
Central nervous system involvement
Presence of active/uncontrolled central nervous system involvement
Patients with any central nervous system involvement or CTCL.
Central nervous system involvement
Central nervous system involvement by lymphoma, including leptomeningeal involvement
EXCLUSION - INFUSION: Patients with central nervous system involvement
Central nervous system involvement
Suggestive central nervous system involvement with leukemia
Central nervous system involvement
Symptomatic central nervous system involvement.
Central nervous system involvement.
Known central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required)
Any active central nervous system or meningeal involvement
Evidence of lymphoma outside of the central nervous system\r\n* Ocular involvement will not exclude
Known central nervous system involvement
Known active involvement of the central nervous system by lymphoma or leukemia
Subjects are not eligible if there is a prior history or current evidence of central nervous system or leptomeningeal involvement
Has either clinical evidence of or history of central nervous system involvement by AML.
Active or previous central nervous system leukemia involvement
Active or previous central nervous system leukemia involvement
Central nervous system involvement with MM (by clinical symptoms and signs).
Active involvement of the central nervous system with malignancy
No known history or suspicion of central nervous system involvement by lymphoma
Central nervous system metastases, including leptomeningeal involvement
Known central nervous system involvement with the disease under study
Primary central nervous system involvement only
Patients with known central nervous system involvement should be excluded from this clinical trial
Has known active central nervous system involvement of the malignancy.
Patients with known or suspected central nervous system involvement of lymphoma.
All patients with central nervous system involvement with lymphoma
Known lymphomatous involvement of the central nervous system
Active involvement of the central nervous system with malignancy
Known active central nervous system involvement
Central nervous system involvement of the disease under study
Central nervous system involvement
Known lymphomatous involvement of the central nervous system
Known central nervous system involvement
Patients must not have active central nervous system involvement
Subjects are not eligible if there is a prior history or current evidence of central nervous system or leptomeningeal involvement
Known central nervous system or meningeal involvement (in the absence of symptoms, investigation into central nervous system involvement is not required)
Central nervous system or meningeal involvement
Active involvement of the central nervous system with malignancy
Active involvement of the central nervous system with malignancy
Central nervous system involvement.
Active central nervous system involvement with AML.
Known central nervous system or meningeal involvement (in the absence of symptoms, investigation into central nervous system involvement is not required)
Known active involvement of the central nervous system by lymphoma or leukemia
Patients with known central nervous system involvement should be excluded from this clinical trial
Central nervous system involvement (Bing-Neel syndrome)
Known involvement of central nervous system
Central nervous system involvement by lymphoma, including leptomeningeal involvement
Clinical evidence of central nervous system involvement.
Known central nervous system involvement or brain metastases
Active central nervous system involvement by leukemia
Active central nervous system involvement
Patients with a history of central nervous system involvement by CLL or who have prolymphocytic leukemia (PLL)
Patients with documented central nervous system involvement of AML
Active central nervous system involvement by malignancy
History of or current, central nervous system involvement with AML.
Known clinically active central nervous system involvement.
Subject has known active central nervous system involvement with AML.
Patients with controlled asymptomatic central nervous system involvement are allowed.
Central nervous system involvement with lymphoma, including parenchymal and leptomeningeal disease
Central nervous system involvement of the CLL
Active uncontrolled central nervous system involvement
Presence or history of central nervous system involvement by lymphoma.
Patients with known central nervous system involvement at the time of study entry will be excluded from this clinical trial
Patients with leukemic involvement of the central nervous system
Central nervous system involvement (based on clinical assessment)
Known clinically active central nervous system involvement
Known active involvement of the central nervous system by lymphoma or leukemia
Central nervous system involvement
Known lymphomatous involvement of the central nervous system.
Known central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required)
Active central nervous system involvement by lymphoma
Known central nervous system involvement
Central nervous system involvement.
Known involvement of the central nervous system by WM.
Central nervous system involvement
Patients with a history of central nervous system involvement by lymphoma
Active involvement of the central nervous system with malignancy
Presence of confirmed distant metastases, including central nervous system and vertebral or meningeal involvement
Central nervous system disease involvement
Central nervous system involvement
Known central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required); patients with human T-cell lymphotropic virus type  (HTLV) adult T-cell leukemia/lymphoma (ATLL) and controlled central nervous system (CNS) or meningeal involvement may be enrolled after discussion with the Memorial Sloan Kettering (MSK) principal investigator
Known active central nervous system involvement
Central nervous system involvement.
Presence or history of central nervous system involvement by lymphoma
Known central nervous system involvement by leukemia
Disease-related central nervous system involvement
Documented current central nervous system involvement by leukemia or lymphoma
CLL central nervous system involvement
No known involvement of central nervous system by lymphoma
Evidence of sanctuary site involvement by disease, e.g., central nervous system, ocular, testicular involvement
Active involvement of the central nervous system with malignancy
Untreated central nervous system involvement
Known central nervous system involvement
Known central nervous system involvement
Active central nervous system involvement by malignancy; central nervous system disease that has been treated into remission is permitted; a chart note of the clinicians impression of lack of central nervous system (CNS) involvement is acceptable
Documented current central nervous system involvement
Symptomatic central nervous system involvement
Known uncontrolled central nervous system involvement
Lymphoma involvement of the central nervous system
For Part B only: Known leukemic involvement or clinical symptoms of leukemic involvement of the central nervous system
Central nervous system involvement
Patients with a history of central nervous system involvement by lymphoma
Patients with known central nervous system involvement.
Patients must not have clinical evidence of central nervous system involvement by lymphoma, since proposed treatment would not be able to address it adequately; any laboratory (e.g., lactate dehydrogenase [LDH]) or radiographic tests performed to access central nervous system (CNS) involvement must be negative and must be performed within  days prior to registration
Known, active (symptomatic) involvement of the central nervous system by leukemia.
Known leukemic involvement of the central nervous system.
Documented current central nervous system involvement by leukemia or lymphoma
Central nervous system involvement
Has central nervous system involvement
History of central nervous system involvement of lymphoma;
All patients with active central nervous system involvement with lymphoma
INCLUSION CRITERIA FOR PATIENTS: No central nervous system involvement of disease
Patients with active central nervous system involvement
Symptomatic central nervous system involvement.
Known uncontrolled central nervous system involvement by malignant disease